Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK120 in Moderate-to-Severe Asthma (Phase II)
CTR20212712Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of manfidokimab in asthma, sponsored by Akeso, Inc.. Started Oct 2021; status: terminated.
02
Drugs
manfidokimab
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20212712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212712.